Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
von hippel-lindau disease
MeSH D006623 - von hippel-lindau disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D020752:
Neurocutaneous syndromes
0 Companies
0 Drugs
Success rate
D000798:
Angiomatosis
0 Companies
0 Drugs
Success rate
D000072661:
Ciliopathies
0 Companies
0 Drugs
Success rate
D006623:
Von hippel-lindau disease
1 Company
1 Drug
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Merck & Co
Belzutifan
Welireg
2034-09-05
2021-08-13
$421 M
Q4/23-Q3/24
Clinical Trials
Historical Success Rate
Phase 1
50
%
3/6
Phase 2
0
%
0/9
Phase 3
100
%
1/1
Approved:
1
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Merck & Co
Belzutifan
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use